Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Reports First-Quarter Results, Adjusts Guidance

By Prosper Junior Bakiny – Updated Apr 23, 2020 at 4:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company posted higher revenue as a result of the COVID-19 pandemic.

Eli Lilly (LLY 8.39%) released its first-quarter earnings before the market opened on Thursday, reporting revenue of $5.9 billion, up 15% year over year. Several of the pharma giant's drugs performed particularly well during the quarter. For instance, sales of the diabetes medication Trulicity hit $1.2 billion, up by 40% compared to the year-ago period. And Eli Lilly's plaque psoriasis treatment Taltz recorded revenue of $443.5 million, which represented a whopping 76% year over year increase.

Not all of the company's products performed well, however. The insulin product Humalog posted revenue of $695.8 million, down by 5% compared to the prior-year quarter. Eli Lilly estimated that during Q1, abnormal buying patterns caused by the ongoing COVID-19 pandemic boosted its revenue by $250 million worldwide.

Smiling pharmacist leaning on a countertop inside a pharmacy.

Image Source: Getty Images.

Eli Lilly reported non-GAAP net income of $1.6 billion, a 29% year over year increase. It had non-GAAP earnings per share of $1.75, up by 32% year over year, and coming in ahead of analysts' consensus  estimate of $1.48.

Management also adjusted their guidance to reflect the impact of the ongoing COVID-19 pandemic. Previously, they had said they expected Eli Lilly's non-GAAP EPS for 2020 to be in the range of $6.70 to $6.80. Now, the pharma giant expects its non-GAAP EPS to be in the range of $6.70 to $6.90.  In other words, Eli Lilly expects the crisis to have a positive impact on its bottom line this year. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$337.19 (8.39%) $26.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.